01443nas a2200229   4500000000100000008004100001260001200042653003900054653001400093653001300107100001500120700001300135700001400148700001300162700001500175245008500190856007800275300001300353490000700366520082600373022001401199       2020                            d  c01/202010aNeglected tropical diseases (NTDs)10adiagnosis10aCovid-191 ade Souza D1 aPicado A1 aBiéler S1 aNogaro S1 aNdung'u JM00aDiagnosis of neglected tropical diseases during and after the COVID-19 pandemic.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428349/pdf/pntd.0008587.pdf  ae00085870 v143 aThe occurrence of coronavirus disease 2019 (COVID-19) causing severe pneumonia and death was first reported in December 2019 in Wuhan, China. This was subsequently revealed to be similar to severe acute respiratory syndrome coronavirus and named SARS-CoV-2 [1]. Since December 2019, more than 20.6 million cases have been reported, with over 749,000 deaths [2]. The urgent need to develop diagnostics for COVID-19 has resulted in the already under-resourced development and manufacturing of rapid diagnostic tests (RDTs) and molecular tests for many tropical diseases being placed on hold. In this article, we assess the impact that COVID-19, and the strategies put in place to control the pandemic, may have on neglected tropical diseases (NTDs), and in particular on the diagnostic capacity and needs of those diseases.  a1935-2735